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Abstract 
The Keap1/Nrf2/ARE pathway enables the cells to survive oxidative stress conditions 
through regulating the expression  of cytoprotective enzymes  such as NAD(P)H:quinone 
oxidoreductase 1 (NQO1). This work presents the design and synthesis of novel 
anilinoquinazoline derivatives (2-16a) and evaluation of their NQO1 inducer activity in 
murine cells. Molecular docking of the new compounds was performed to assess their 
ability to inhibit Keap1-Nrf2 protein-protein interaction through occupying the Keap1 
Nrf2-binding domain which leads to Nrf2 accumulation and enhanced gene expression of 
NQO1. The docking results showed that all compounds can potentially interact with 
Keap1, however, 1,5-Dimethyl-2-phenyl-4-(2-phenylquinazolin-4-ylamino)-1,2-
dihydropyrazol-3-one (9), the most potent inducer, showed the largest number of 
interactions with key amino acids in the binding pocket (Arg483, Tyr525 and  Phe478) 
compared to the native ligand or any other compound in this series.  
 
Keywords: anilinoquinazoline, molecular modeling, Keap1/Nrf2, cytoprotection, NQO1 
induction. 
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Introduction 
Antioxidants, from a chemical viewpoint, are considered electron donors to free radicals, 
molecular centers that tend to lose electrons initiating oxidations, and thus protecting the 
cells against oxidative stress1-3. Such oxidative stress situations, generated from 
imbalanced production of reactive oxygen species (ROS), e.g. superoxide anion radical 
(O2-) and hydrogen peroxide (H2O2), is unfortunately associated with many pathological 
conditions including stroke, diabetes, Alzheimer’s disease, cancer and chronic 
inflammation4. As a natural mechanism to counteract oxidative stress, aerobic cells 
express superoxide dismutase converting superoxide to hydrogen peroxide, which is 
subsequently disposed by catalase and peroxidases. In addition to these enzymatic 
defenses, there are the indirect antioxidants,” namely, the cytoprotective enzymes, that 
catalyze a wide variety of chemical reactions, protecting cells and organisms and 
allowing their adaptation to many types of stress5.  Among the most critical 
cytoprotective enzymes is the Kelch-like ECH-associated protein 1 (Keap1)-nuclear 
factor erythroid 2-related factor 2 (Nrf2)-antioxidant response elements (AREs) 
pathway6,7. The Keap1/Nrf2/ARE pathway enables the cells in adapting and surviving 
oxidative and inflammatory stress conditions through regulating the expression of a 
network of more than 100 cytoprotective genes. This pathway is inducible by various 
stress stimuli and small molecules (termed inducers), whereby the inducers react with 
specific cysteine residues of the protein sensor Keap1, which loses its ability to target 
Nrf2 for ubiquitination and proteasomal degradation, resulting in its stabilization, 
followed by binding to the ARE and transcriptional activation of cytoprotective genes, 
such as NAD(P)H: quinone oxidoreductase 1 (NQO1)6, 8-11. Recently, the Keap1-Nrf2 
protein-protein interaction is viewed as a critical target for intervention and potential 
management of a variety of oxidative stress-related pathologies, including cancer, 
Parkinson’s and Alzheimer’s disease, and diabetes12-15. Design of non-covalent small 
molecule modulators of the Keap-Nrf2 interaction has been intensively explored16,17. 
Quinazoline derivatives are considered excellent bioactive substances where a number of 
biological activities have been associated with antioxidant activity18-20. 
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In continuation of our work towards identification of NQO1 inducers21, 22, we herein 
report the synthesis, NQO1 inducer activity and Keap1 binding in silico screening results 
for a novel class of anilinoquinazolines. 
 
Materials and methods 
Chemistry 
Melting points (uncorrected) were determined in open capillaries on a Gallen Kamp 
melting point apparatus (Sanyo Gallen Kamp, UK). Pre-coated silica gel plates (Kieselgel 
0.25 mm, 60 G F 254; Merck, Germany) were used for thin layer chromatography. A 
developing solvent system of chloroform/methanol (8:2 mL) mixture was used and the 
spots were detected by ultraviolet light. IR spectra (KBr disc) were recorded using an FT-
IR spectrophotometer (Perkin Elmer, USA). NMR spectra were scanned on a NMR 
spectrophotometer (Bruker AXS Inc., Switzerland), operating at 500 MHz for 1H spectra 
and 125.76 MHz for 13C spectra. Chemical shifts are expressed in δ-values (ppm) relative 
to TMS as an internal standard, using DMSO-d6 as a solvent. Elemental analyses were 
done on a model 2400 CHNSO analyzer (Perkin Elmer, USA). All the values were within 
± 0.4 % of the theoretical values. All reagents used were of AR grads. The starting 
material 4-chloro-2-phenylquinazoline 1 was purchased from sigma (USA) and was 
directly used for preparation of the target compounds. 
 
General procedure for the Synthesis of 2-phenyl-quinazoline-4-amine derivatives (2-
16a). 
A mixture of 1 (2.40 g, 0.01 mol) and different amines (0.012 mol) in dry 
dimethylformamide (10 mL) containing trimethylamine 3 drops was refluxed for 24 h. , 
then left to cool. The solid product formed was collected by filtration and recrystallized 
from acetic acid to give 2-16a, respectively. 
 
N-Heptyl-2-phenylquinazolin-4- amine (2) 
Yield, 87%; m.p. 141.3 oC. IR (KBr, cm-1): 3278 (NH), 3074 (CH arom.), 2924, 2950, 
2851 (CH aliph.), 1639 (C=N). 1H-NMR (DMSO-d6): 0.9 (t, 3H, CH3), 1.2 [m, 10H, 
5CH2], 3.8 [t, 2H, CH2-NH], 7.6-8.7 [m, 9H, Ar-H], 10.8 [s, 1H, NH exchangeable with 
D2O]. 
13C-NMR (DMSO-d6): 14.3, 22.5, 26.8, 28.9, 31.5, 31.6, 42.1, 112.6, 120.3, 124.8 
(2), 128.2, 129.3, 129.5, 131.7, 133.8, 135.5, 139.5, 157.3, 160.2. MS m/z (%):  319 (M+) 
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(3.23), 204 (100). Anal. Calcd. For C21H25N3 (319): C, 78.96; H, 7.89; N, 13.15. Found: 
C, 78.59; H, 8.13; N, 12.81. 
 
N-(Octan-2-yl)-2-phenylquinazolin-4-amine (3) 
Yield, 80%; m.p. 192.8 oC. IR (KBr, cm-1): 3191 (NH), 3100 (CH arom.), 2954, 2925, 
2850 (CH aliph.), 1629 (C=N). 1H-NMR (DMSO-d6): 0.7 [t, 3H, CH3], 0.8 [d, 3H, CH3          
, J = 7.2 Hz], 1.2-1.8 [m, 10H, 5CH2], 2.8 [m, 1H, CH], 7.6-8.8 [m, 9H, Ar-H], 10.0 [s, 
1H, NH exchangeable with D2O]. 
13C-NMR (DMSO-d6): 14.3, 20.3, 21.2, 25.8, 28.8, 
31.6, 36.4, 48.6, 112.5, 120.4, 124.9 (2), 128.2, 129.4, 129.6 (2), 131.9, 133.8, 136.0, 
157.5, 159.8, 160.6. MS m/z (%):  333 (M+) (12.7), 255 (100). Anal. Calcd. For C22H27N3 
(333.47): C, 79.24; H, 8.16; N, 12.60. Found: C, 79.50; H, 7.84; N, 12.25. 
 
2-Phenyl-N-(2-(pyrrolidin-1-yl)ethyl)quinazolin-4-amine (4) 
Yield, 90%; m.p. 93.9 oC. IR (KBr, cm-1): 3325 (NH), 358 (CH arom.), 2935, 2846 (CH 
aliph.), 1617 (C=N).  1H-NMR (DMSO-d6): 1.4-1.5 [m, 4H, CH2-CH2 Cyclo], 2.4-2.5 [ 
m, 4H, CH2-N-CH2 Cyclo], 2.6 [t, 2H, N-CH2], 3.8 [t, 2H, CH2-NH], 7.8-8.5 [m, 10H, 
Ar-H + NH].  13C-NMR (DMSO-d6): 24.5 (2), 40.5, 54.7, 57.7 (2), 114.3, 123.0, 125.6 
(2), 128.3, 128.6, 128.7 (2), 130.4, 133.0, 139.2, 150.3, 159.7, 160.1. MS m/z (%):  318 
(M+) (22.5), 247 (100). Anal. Calcd. For C20H22N4 (318): C, 75.44; H, 6.96; N, 17.60. 
Found: C, 75.09; H, 6.63; N, 17.92. 
 
N-(2-(1-Methylpyrrolidin-2-yl)ethyl)-2-phenylquinqzolin-4-amine (5) 
Yield, 85%; m.p. >360 oC. IR (KBr, cm-1): 3308 (NH), 3060 (CH arom.), 2950, 2819, 
(CH aliph.), 1618 (C=N). 1H- NMR (DMSO-d6): 1.7-2.3 [m, 6H, 3CH2 Cyclo], 1.9 [m, 
2H, CH2-CH], 2.4 [m, 1H, CH Cyclo], 2.5 [s, 3H, N-CH3], 3.0 [m, 2H, CH2-NH], 7.4-8.6 
[m, 10H, Ar-H + NH]. 13C- NMR (DMSO-d6): 21.4, 29.4, 29.5, 40.4, 40.5, 55.2, 66.0, 
114.3, 123.4, 125.7 (2), 128.2, 128.3, 128.7 (2), 130.5, 133.2, 139.1, 150.3, 159.7, 160.2. 
MS m/z (%):  332 (M+) (21.6), 316 (100). Anal. Calcd. For C21H24N4 (332): C, 75.87; H, 
7.28; N, 16.85. Found: C, 76.11; H, 7.57; N, 17.20. 
 
N-(2-(1-Methyl-1H-pyrrol-2-yl)ethyl)-2-phenylquinqzolin-4-amine (6) 
Yield, 82%; m.p. 172.7 oC. IR (KBr, cm-1): 3334 (NH), 3059 (CH arom.), 2930, 2825 
(CH aliph.), 1618 (C=N). 1H-NMR (DMSO-d6): 1.9 (s, 3H, CH3), 2.8-3.9 [m, 4H, 2CH2], 
5.6-6.6 [m, 3H, 3CH Pyrrole], 7.5-8.5 [m, 10H, Ar-H + NH]. 13C-NMR (DMSO-d6): 
25.9, 33.6, 41.0, 106.4, 106.7, 114.3, 121.8, 123.0, 125.5, 125.7 (2), 128.1, 128.3, 128.6 
(2), 130.4, 133.1, 133.4, 150.4, 159.8, 162.7. MS m/z (%):  328 (M+) (3.26), 248 (100). 
Anal. Calcd. For C21H20N4 (328): C, 76.80; H, 6.14; N, 17.06. Found: C, 76.55; H, 6.47; 
N, 16.81. 
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1-(3-(2-Phenylquinazolin-4-ylamino)propylpyrrolidin-2-one (7) 
Yield, 88%; m.p. >360 oC. IR (KBr, cm-1): 3370(NH), 3100 (CH arom.), 2932, 2847, 
(CH aliph.), 1654 (C=O), 1572 (C=N). 1H-NMR (DMSO-d6): 1.5-3.2 [m, 6H, 3CH2 
Cyclo], 1.9 [m, 2H, CH2-CH2-CH2], 3.3-3.5 [m, 4H, NH-CH2 +N-CH2], 7.3-8.8 [m, 10H, 
Ar-H + NH]. 13C-NMR (DMSO-d6): 18.5, 20.5, 29.1, 40.3, 40.4, 56.5, 114.3, 123.1, 
125.8 (2), 128.3, 128.6, 130.5 (2), 133.1, 135.7, 139.1, 150.3, 159.6, 160.1, 183.2. MS 
m/z (%):  346 (M+) (15.38), 317 (100). Anal. Calcd. For C21H22N4O (346): C, 72.81; H, 
6.40; N, 16.17. Found: C, 72.54; H, 6.08; N, 16.46. 
 
N-(1-Ethyl-1H-pyrazol-5-yl)-2-phenylquinazolin-4-amine (8) 
Yield, 92%; m.p. 243.5 oC. IR (KBr, cm-1): 3414 (NH), 3062 (CH arom.), 2956, 2854 
(CH aliph.), 1617 (C=N). 1H-NMR (DMSO-d6): 1.3 [t, 3H, CH3], 4.3 [q, 2H, CH2], 7.4-
8.5 [m, 11H, Ar-H], 12.5 [s, 1H, NH exchangeable with D2O]. 
13C-NMR (DMSO-d6): 
16.2, 40.4, 93.8, 114.6, 121.4, 126.3 (2), 127.0, 127.8, 128.2 (2), 129.0, 131.8, 133.2, 
135.0, 149.1, 152.9, 162.8 (2).  MS m/z (%):  315(M+) (9.54), 286 (100). Anal. Calcd. 
For C19H17N5 (315): C, 72.36; H, 5.43; N, 22.21. Found: C, 72.69; H, 5.16; N, 22.51. 
 
1,5-Dimethyl-2-phenyl-4-(2-phenylquinazolin-4-ylamino)-1,2-dihydropyrazol-3-one (9). 
Yield, 84%; m.p. 149.4 oC. IR (KBr, cm-1): 3413 (NH), 3060 (CH arom.), 2923, 2839, 
(CH aliph.), 1654 (C=O), 1618 (C=N). 1H-NMR (DMSO-d6): 2.3 [s, 3H, CH3], 3.1 [s, 
3H, N-CH3], 7.3-8.5 [m, 14H, Ar-H], 9.4 [s, 1H, NH exchangeable with D2O]. 
13C-NMR 
(DMSO-d6): 11.6, 31.2, 114.2 (2), 123.6, 124.0 (2), 126.2, 126.7 (2), 128.2, 128.4, 128.7 
(2), 129.6 (2), 130.6 (2), 133.5, 135.9, 138.8, 150.8, 159.5, 160.1, 162.7. MS m/z (%):  
407 (M+) (5.98), 331 (100). Anal. Calcd. For C25H21N5O (407): C, 73.69; H, 5.19; N, 
17.19. Found: C, 73.44; H, 5.50; N, 17.56. 
 
N-(3-(1H-Imidazol-1-yl)propyl)-2-phenylquinazolin-4-amine (10) 
Yield, 79%; m.p. 174.5 oC. IR (KBr, cm-1): 3231 (NH), 3058 (CH arom.), 2927, 2866 
(CH aliph.), 1617 (C=N). 1H-NMR (DMSO-d6): 2.1-4.1 [m, 6H, CH2-CH2-CH2-N], 7.2-
8.4 [m, 12H, Ar-H], 8.5 [s, 1H, NH exchangeable with D2O]. 
13C-NMR (DMSO-d6): 
30.6, 40.5, 44.4, 114.3, 119.9, 123.1, 125.7 (2), 128.3, 128.6, 128.8, 130.5 (2), 133.1 (2), 
137.8, 139.0, 150.3, 159.6, 160.1.   MS m/z (%):  329 (M+) (17.23), 288 (100). Anal. 
Calcd. For C20H19N5 (329): C, 72.93; H, 5.81; N, 21.26. Found: C, 72.71; H, 5.49; N, 
20.93. 
 
N-(3-(2-Methylpiperidin-1-yl)propyl)-2- phenylquinazolin-4-amine (11) 
Yield, 84%; m.p. 254.7 oC. IR (KBr, cm-1): 3434(NH), 3089 (CH arom.), 2957, 2779, 
(CH aliph.), 1633 (C=N). 1H-NMR (DMSO-d6): 1.2 [s, 3H, CH3], 1.3-2.6 [m, 9H, 4CH2 
+ CH Cyclo], 1.6-3.8 [m, 6H, 3CH2], 7.4-8.9 [m, 9H, Ar-H], 10.8 [s, 1H, NH 
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exchangeable with D2O]. 
13C-NMR (DMSO-d6): 12.3, 22.2, 23.5, 27.9, 34.4, 40.4, 50.1, 
55.1, 59.0, 112.9, 120.9, 125.0 (2), 128.2 (2), 129.3 (2), 129.8, 133.7, 135.8, 157.6 (2), 
160.6. MS m/z (%):  360 (M+) (33.85), 344 (100). Anal. Calcd. For C23H28N4 (360): C, 
76.63; H, 7.83; N, 15.54. Found: C, 76.91; H, 7.49; N, 15.22. 
 
2- Phenyl-N-(2-piperidin-1-yl)ethyl)quinazolin-4-amine (12) 
Yield, 90%; m.p. 317.5 oC. IR (KBr, cm-1): 3401 (NH), 3100 (CH arom.), 2936, 2713 
(CH aliph.), 1630 (C=N). 1H-NMR (DMSO-d6): 2.2-2.7 [m, 10H, 5CH2 Cyclo], 2.8 [t, 
2H, N-CH2], 4.3 [s, 2H, CH2NH], 7.4-9.1 [m, 9H, Ar-H], 10.2 [s, 1H, NH exchangeable 
with D2O]. 
13C-NMR (DMSO-d6): 24.5, 28.0 (2), 47.4, 50.7, 59.4 (2), 112.6, 120.5, 125.0 
(2), 128.1, 128.2, 129.4 (2), 130.4, 131.5, 133.9, 157.4, 160.2, 162.8.  MS m/z (%):  
332(M+) (45.11), 219 (100). Anal. Calcd. For C21H24N4 (332.20): C, 75.87; H, 7.28; N, 
16.85. Found: C, 76.11; H, 7.55; N, 17.10. 
 
N-(2-Morpholinoethyl)-2-phenylquinazolin-4-amine (13) 
Yield, 76%; m.p. 273.4 oC. IR (KBr, cm-1): 3413 (NH), 3076 (CH arom.), 2927, 2836 
(CH aliph.), 1599 (C=N). 1H-NMR (DMSO-d6): 2.3-2.4 [m, 4H, CH2-N-CH2 
morpholino], 2.5-3.2 [m, 4H, 2CH2], 3.6-4.3 [m, 4H, CH2-O-CH2], 7.3-8.8 [m, 9H, Ar-
H], 10.3 [s, 1H, NH exchangeable with D2O]. 
13C-NMR (DMSO-d6): 51.5, 54.9, 55.4 (2), 
63.7 (2), 113.3, 126.9, 127.8 (2), 129.6 (2), 129.8 (2), 133.1 (2), 135.5, 159.1, 160.2, 
163.4.  MS m/z (%):  334 (M+) (22.17), 256 (100). Anal. Calcd. For C20H22N4O (334): C, 
71.83; H, 6.63; N, 16.75. Found: C, 71.50; H, 6.30; N, 16.45. 
 
N-(3-Morpholinopropyl)-2-phenylquinazolin-4-amine (14) 
Yield, 80%; m.p. 235.8 oC. IR (KBr, cm-1): 3324 (NH), 3088 (CH arom.), 2954, 2864 
(CH aliph.), 1610 (C=N). 1H-NMR (DMSO-d6): 1.8-1.9 [m, 2H, NH-CH2-CH2-CH2], 
2.2-2.3 [m, 4H, CH2-N-CH2 morpholino], 3.1 [t, 2H, N-CH2], 3.2 [t, 2H, NH-CH2], 3.8-
3.9 [m, 4H, CH2-O-CH2], 7.5-8.5 [m, 9H, Ar-H], 11.2 [s, 1H, NH exchangeable with 
D2O]. 
13C-NMR (DMSO-d6): 23.7, 40.5, 51.4, 54.3 (2), 63.6 (2), 113.9, 123.8, 128.8 (2), 
128.9 (2), 129.6 (2), 132.7, 133.1, 135.6, 152.2, 160.3, 161.7. MS m/z (%):  348 (M+) 
(10.62), 221 (100). Anal. Calcd. For C21H24N4O (348): C, 72.39; H, 6.94; N, 16.08. 
Found: C, 72.08; H, 6.60; N, 16.35. 
 
N-(1-Benzylpiperidin-2-yl)-2-phenylquinazolin-4-amine (15) 
Yield, 83%; m.p. 250.9 oC. IR (KBr, cm-1): 3380 (NH), 3077 (CH arom.), 2988, 2867 
(CH aliph.), 1630 (C=N). 1H-NMR (DMSO-d6): 2.1-2.8 [m, 9H, 4CH2 + CH Cyclo], 4.3 
[s, 2H, CH2-Ph], 7.4-8.9 [m, 14H, Ar-H], 10.2 [s, 1H, NH exchangeable with D2O].               
13C-NMR (DMSO-d6): 22.6, 28.0, 34.5, 50.7, 59.4, 83.2, 112.6, 125.0, 128.2, 129.2 (2), 
129.4 (3), 129.9 (3), 130.4 (2), 131.5, 132.0, 133.9, 136.1, 157.5, 160.2, 162.8. MS m/z 
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(%):  394 (M+) (5.88), 314 (100). Anal. Calcd. For C26H26N4 (394.22): C, 79.16; H, 6.64; 
N, 14.20. Found: C, 79.48; H, 6.36; N, 13.83. 
 
6-(2-Penylquinazolin-4-ylamino)hexanoic acid (16a) 
Yield, 76%; m.p. 164.6 oC. IR (KBr, cm-1): 3438 (OH), 3311 (NH), 3078 (CH arom.), 
2939, 2854 (CH aliph.), 1687 (C=O), 1613 (C=N). 1H-NMR (DMSO-d6):1.4-1.8 [m, 6H, 
3CH2], 2.2 [t, 2H, CH2CO], 3.8 [t, 2H, NH-CH2], 7.3-8.8 [m, 9H, Ar-H], 10.5 [s, 1H, 
NH exchangeable with D2O], 14.9 [s, 1H, OH exchangeable with D2O]. 13C-NMR 
(DMSO-d6): 24.6, 26.3, 28.3, 34.0, 41.9, 112.6, 126.8, 128.2 (2), 129.4 (2), 129.6 (2), 
133.7 (2), 135.8, 157.4 (2), 160.2, 174.8. MS m/z (%):  335 (M+) (39.45), 290 (100). 
Anal. Calcd. For C20H21N3O2 (335): C, 71.62; H, 6.31; N, 12.53. Found: C, 71.29; H, 
6.60; N, 12.19. 
 
Biological evaluation 
Hepa1c1c7 murine hepatoma cells were grown in a humidified atmosphere at 37 oC, 5% 
CO2. The cell culture medium was -MEM supplemented with 10% (v/v) heat- and 
charcoal-inactivated fetal bovine serum. For evaluation of the potential NQO1 inducer 
activity, cells (104 per well) were grown in 96-well plates for 24 h, after which the cell 
culture medium was replaced with fresh medium containing each inducer (dissolved in 
DMSO and diluted in the medium 1:1000), and the cells were grown for a further 48 h. 
There were eight replicates of each treatment of serial dilutions of inducers. The final 
DMSO concentration in the cell culture medium was maintained 0.1% (v/v) in all wells. 
At the end of the treatment period, cell lysates were prepared in digitonin and the specific 
activity of NQO1 was determined using menadione as a substrate as described23,24. The 
Concentration which Doubles the specific activity of NQO1 (CD value) was used as a 
measure of inducer potency. Mean values for the eight replicate wells are shown for each 
data point. The standard deviation for each data point was within 5% of the mean value. 
 
Molecular modeling study 
The molecular model of all the new anilinequinazoline derivatives was built using MOE 
software suite version 10.2008 maintaining all the default parameters. The structures’ 
geometry was optimized and a systematic conformational search was carried out to an 
RMS gradient of 0.01Å using the ConfSearch module implemented in MOE. 
Computations were set to be performed with the Merck Force Field (MMFF94s). The 
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new compounds’ ability to access and block the Nrf2-binding site of Keap1 was 
evaluated by performing a molecular docking study using the crystallographic structure 
of Keap1 obtained from the Protein Data Bank (PDB ID: 4IQK). Following addition of 
the missing hydrogens and calculating the partial charges of the receptor, validation of 
the docking has been carried out by docking of the native ligand. Afterwards, the ligands 
were docked where they were left free to explore all conformations possible inside the 
enzyme. Multiple separate docking simulations using default parameters were performed 
followed by choosing the best conformations based on the combination of  S score data, 
E conformation and appropriate fitting with the relevant amino acids in the binding 
pocket. 
 
 
Results and Discussion 
Chemistry 
The new anilinoquinazolines derivatives 2-16a that were designed for the aim of 
exploring their potential cytoprotective activity, were synthesized from the key starting 
material 4-chloro-2-phenylquinazoline 1 by allowing it to react with primary amines with 
their side chains bearing aliphatic groups (e.g. heptane, octane), aromatic groups (e.g. 
pyrrolidine, imidazole, piperidine) or substituted aromatic rings (e.g. methyl pyrrolidine, 
benzyl piperidine, methyl piperidine). Refluxing of 1 with the amines in dry 
dimethylformamide in the presence of triethylamine as a catalyst yielded the desired 
corresponding compounds 2-16a with good yield values. (Scheme 1 and 2) The 
structures of the products were assigned on the basis of their analytical and spectral data. 
First, the IR spectra of the reaction products showed in all compounds an absorption band 
corresponding to NH function in the region 3434-3191 cm-1, in addition to a C=N band in 
the region 1639-1572 cm-1. Moreover, compounds 7, 9 and 16a have shown an extra 
carbonyl absorption band in the region 1687-1654 cm-1. Finally, Compounds 4-16a 
bearing aliphatic carbon chains have shown absorption peaks around 2988-2713 cm-1. 
Moreover, 1H-NMR spectra of compounds 2–16a in (DMSO-d6) revealed a singlet signal 
that was exchangeable with D2O in the region 9.4-11.2 ppm corresponding to a NH 
group. Regarding compound 16, compound 1 was reacted with 6-aminocaproic acid with 
the expected product to be azepan-2-one derivative 16b, however, the hexanoic acid 
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derivative 16a was obtained instead. That was revealed on the basis of elemental analysis 
and IR spectrum which showed the presence of OH absorption band at 3438 cm-1, NH 
band at 3311 cm-1 and a carbonyl band at 1687 cm-1. That  was further confirmed using 
spectral analysis where 1H-NMR  showed  a triplet at 3.8 ppm for the NH-CH2, signal at 
10.5 ppm for the NH group which is exchangeable with D2O and another signal at 14.9 
ppm for the OH group which is exchangeable with D2O. Moreover, 
13C- NMR of 16a 
revealed signals at 24.6 ppm for CH2-CH2-COOH, 26.3 ppm for CH2-CH2-CH2-COOH , 
28.3 ppm for NH-CH2-CH2, 34.0 ppm for CH2-COOH, 41.9 ppm for NH-CH2, 174.8 
ppm for C=O group. These assignments fully support and affirm the proposed structure.  
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Biological activity 
12 
 
The ability of the novel compounds to duplicate the activity of NAD(P)H:quinone 
oxidoreductase 1 (NQO1) was used as a measure of  their cytoprotective activity (CD 
values). Evaluation of the NQO1 inducer activity showed that compounds 2, 5 and 14 
were inactive, whereas compounds 4, 6, 11, 12, 13, and 16a had weak activity, however, 
CD value was not reached (Figure 1). On the other hand, compounds 3 (CD = 14 µM), 7 
(CD = 26 µM) and 15 (CD = 19 µM) had moderate inducer activity. Compounds 8 (CD = 
5.2 µM) and 10 (CD = 5.5 µM) were of approximately equal potency. However, the cell 
responses to them were very different where the dose-response dependency was very 
clear for compound 8, whereas it was completely absent for compound 10. The most 
potent inducer in this series was compound 9 (CD = 3.9 µM), which also showed a very 
clear dose response with a magnitude of induction of ~6-fold at a concentration of 50 
µM. 
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Table 1: NQO1 inducer activity and CD values of the test compounds. 
 
*NR = Not Recorded 
** CD data presented are the averages of 3 independent experiments, each with 8 replicate wells of cells, 
and SD (standard deviation) for each data point was within 5% of the value. 
 
  
Figure 1: Concentration dependence of NQO1 inducer activity of quinazoline derivatives. 
Conc. 
(uM) 
Compound # 
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16a 
0.1563 NR* 1.05 NR NR NR NR NR NR NR NR NR NR NR NR NR 
0.3125 NR 1.08 NR NR NR NR NR NR NR NR NR NR NR NR NR 
0.625 NR 1.07 NR NR NR NR NR NR NR NR NR NR NR NR NR 
0.781 1.25 NR 1.24 1.09 0.97 1.01 1.23 1.34 1.66 1.11 1.01 1.12 1.01 1.12 1.04 
1.25 NR 1.19 NR NR NR NR NR NR NR NR NR NR NR NR NR 
1.563 1.25 NR 1.3 1.1 0.96 1.01 1.33 1.56 1.78 1.1 1.12 1.17 1.04 1.14 1.04 
2.5 NR 1.28 NR NR NR NR NR NR NR NR NR NR NR NR NR 
3.125 1.21 NR 1.49 1.12 1.08 1.1 1.57 1.86 1.89 1.2 1.26 1.16 1.06 1.23 1.1 
5 NR 1.56 NR NR NR NR NR NR NR NR NR NR NR NR NR 
6.25 1.2 NR 1.68 1.2 1.31 1.25 2.12 2.41 2.03 1.3 1.36 1.24 1.11 1.38 1.23 
10 NR 1.93 NR NR NR NR NR NR NR NR NR NR NR NR NR 
12.5 NR NR 1.76 1.28 1.54 1.48 2.63 3.23 2.1 1.5 NR 1.39 1.1 1.67 1.45 
20 NR 2.13 NR NR NR NR NR NR NR NR NR NR NR NR NR 
25 NR NR NR NR NR 1.98 3.34 4.74 NR NR NR 1.41 1.06 2.22 1.53 
50 NR NR NR NR NR 2.73 4.16 6.45 NR NR NR NR NR 3.19 NR 
100 NR NR NR NR NR 3.63 4.25 NR NR NR NR NR NR 4.02 NR 
CD** NR 14 NR NR NR 26 5.2 3.9 5.5 NR NR NR NR 19 NR 
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Molecular modeling 
It has been established that binding of Keap1 to Nrf2 promotes its degradation, thus 
maintaining low levels of expression of cytoprotective gene products. Several small 
molecule compounds have been reported to have binding affinity to the Keap1 Kelch 
domain therefore antagonizing its activity25, 26. In order to assess  the ability of the newly 
synthesized compounds to access and block the Kelch domain of Keap1, a molecular 
docking study was performed using the crystal structure obtained from the Protein Data 
Bank (PDB ID: 4IQK) using MOE software suite version 10.2008. The key interactions 
detected between the validated native ligand and the receptor are found to be arene-cation 
interaction with Arg415, arene-arene interaction with Tyr525 and 3 hydrogen bonds with 
Ser602, Ser508 and Ser555 with S = -13.306 Kcal/mol with a rmsd of 0.6635 Kcal/mol/Å 
(Figure 2). Docking of the synthesized compounds revealed that binding to Arg415 
through an arene-cation interaction is an important common interaction among all 
compounds. Moreover, by observing the interactions of compounds 4-16a it was found 
that compounds showing activity have a larger number of interactions with the binding 
site of the sensor protein via their side chain or via their main skeleton. That may 
emphasize the role of variation of the side chain in either making its own interactions or 
in pushing the phenylquinazoline moiety to more interactions with more amino acids. 
By having a further insight of compound 9 that showed the best activity (CD = 3.9 µM), 
it was obvious that it also showed the best binding affinity with S = - 11.7347 Kcal/mol. 
Compound 9 is able to make two arene-cation interactions with Arg483. Although that 
Arg is different from Arg415 that the native ligand interact with, the overlap of 
compound 9 over the native ligand showed a change in the orientation of the compound 
to ensure better fitting in the pocket. (Figure 3). Moreover, an arene-arene interactions is 
noticed with Tyr525 similar to the native ligand. Finally an additional arene-arene 
interaction is noticed with Phe478; that additional interaction may be related to the high 
activity of that compound since it is only noticed in the interactions of compound 9 with 
the sensor. (Figure 4)   
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Figure 2: Interactions of the native ligand with the Kelch domain of Keap1 (PDBID: 41QK) 
 
 
 
 
 
Figure 3: Overlap of compound 9 (magenta) over native ligand (cyan) the Kelch domain of Keap1. 
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Figure 4: Interactions of Compound 9 with the Kelch domain amino acids of Keap1.  
 
 
Conclusion 
In conclusion, this study deals with the synthesis of novel anilinoquinazoline derivatives 
with potential cytoprotective NQO1 inducing activity. Among the derivatives 2-16a, 
twelve compounds showed activity, with six of them showing CD values ranging 
between 3.9- 25 µM. Finally, the molecular docking study has shown that the most active 
derivative, compound 9 (CD = 3.9 µM), showed arene-arene interactions with key amino 
acids in the active pocket of Keap1. The obtained results introduce compound 9 as a lead 
for anilinoquinazoline scaffold-based cytoprotective agents thus serving as a starting 
point for lead optimization of new molecules based on the chemotype described herein. 
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